1. Home
  2. CPZ vs KROS Comparison

CPZ vs KROS Comparison

Compare CPZ & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calamos Long/Short Equity & Dynamic Income Trust

CPZ

Calamos Long/Short Equity & Dynamic Income Trust

N/A

Current Price

$13.60

Market Cap

252.9M

Sector

Finance

ML Signal

N/A

Logo Keros Therapeutics Inc.

KROS

Keros Therapeutics Inc.

N/A

Current Price

$10.63

Market Cap

206.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CPZ
KROS
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
252.9M
206.0M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
CPZ
KROS
Price
$13.60
$10.63
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$21.86
AVG Volume (30 Days)
83.1K
185.4K
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
146.00
EPS
N/A
N/A
Revenue
N/A
$243,864,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2,751.79
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.41
$9.69
52 Week High
$16.82
$22.55

Technical Indicators

Market Signals
Indicator
CPZ
KROS
Relative Strength Index (RSI) 67.90 51.81
Support Level $12.78 $10.57
Resistance Level $15.13 $11.55
Average True Range (ATR) 0.25 0.48
MACD 0.06 0.08
Stochastic Oscillator 84.97 62.42

Price Performance

Historical Comparison
CPZ
KROS

About CPZ Calamos Long/Short Equity & Dynamic Income Trust

Calamos L/S Equity & Dynamic Inc Trust is a trust company that seeks to provide current income and risk-managed capital appreciation, with an investment objective to deliver total return through a combination of capital appreciation and current income. The Fund invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary, and others, and holds securities with a broad range of maturities, with the average term to maturity typically ranging from two to ten years. Managed assets represent the Fund's total assets, including any assets attributable to leverage that may be outstanding, minus total liabilities other than debt representing financial leverage.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: